Clin2
NCT05377047Possibly a fitRecruiting

Targeted radiation for limited recurrent breast cancer spread

Breast Cancer Stage IVOligometastatic Disease

Part of Cancer, Skin clinical trials.

This trial tests whether a precise form of high-dose radiation can control up to 1–5 breast cancer metastases (spread) in a few body areas. It may help by focusing treatment only on visible spots while limiting radiation to the rest of the body.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
345 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have breast cancer that has returned, with 1 to 5 metastases in no more than two organs
  • Your scans (PET-CT) show the number and location of metastases, and you can have imaging with CT or MRI
  • You are 18 or older and are healthy enough for treatment (performance status 0 to 2) and expected to live more than 6 months
  • If you’ve already had treatment, your cancer is not clearly worsening right now (it’s stable after the first treatment line), and you can have the required records
  • If you can have pregnancy, you must take reliable birth control and have a recent negative pregnancy test
  • You must not have certain exclusions (like brain metastases, uncontrolled spinal cord risk, or fluid buildup from cancer in the lung or belly)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05784428Recruiting
Radiation “spot treatments” for a few metastatic or worsening spots

This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.

Kelowna, British Columbia
NCT05679427Recruiting
Surgery-like radiation for limited bone spread

This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.

Milan, MI
NCT06556550Recruiting· Phase 2/Phase 3
Targeted radiation for limited cancer spread vs. standard care

This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.

Obninsk, Kaluga Oblast
NCT06918951Recruiting
Stereotactic radiation vs standard radiation for limited cancer spread

This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.

Surrey, British Columbia
NCT05508464Recruiting
Test targeted radiation to control many metastases safely

This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.

London, Ontario
NCT04989725Recruiting· Phase 2
Precision radiation for a few new cancer spots while on treatment

This trial tests a precise, high-dose radiation technique (SABR) for people whose cancer has started to grow again in only a few spots despite ongoing medication. The goal is to control those new growths while continuing your current treatment.

Montreal, Quebec

Hear when a new Breast Cancer Stage IV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.